Protective effects of quercetin on streptozotocininduced diabetic nephropathy in rats

Phytotherapy Research

Volumn 27, Issue 10, 2013, Pages

  Hao, Hui Hui ^a   Lu, Qian ^a   Tang, Dao Quan ^a   Shao, Zhu Min ^a   Yin, Xiao Xing ^a   Mou, Jie ^a   Du, Qian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CTGF; Diabetic nephropathy; Oxidative stress; Quercetin; Smads; TGF 1

Indexed keywords

ARTICLE; RETRACTED ARTICLE;

EID: 84871576419     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4910     Document Type: Article

References (32)

1. Anjaneyulu M, Chopra K. 2004. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 31: 244-248.
2. Balakumar P, Chakkarwar VA, Krishan P, Singh M. 2009. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy. Biomed Pharmacother 63: 171-179.
3. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
4. Cooper ME. 2001. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 449: 1957-1972.
5. Fioretto P, Mauer M. 2007. Histopathology of diabetic nephropathy. Semin Nephrol 27: 195-207.
6. Fukami K,Ueda S, Yamagishi S, Kato S, InagakiY, Takeuchi M. 2004. AGEs activatemesangial TGF-beta-Smad signaling via an angiotensin II type 1 receptor interaction. Kidney Int 66: 2137-2147.
7. Gagliardini E, Benigni A. 2006. Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 17: 89-96.
8. Guhua Z, Cai L, Lu C. 2004. Advanced glycation end products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165: 2033-2043.
9. Ha H, Lee HB. 2001. Oxidative stress in diabetic nephropathy:basic and clinical information. Curr Diab Rep 1: 282-287.
10. Haque N, Salma U, Nurunnabi TR, et al. 2011. Management of type 2 diabetes mellitus by lifestyle, diet and medicinal plants. Pak J Biol Sci 14: 13-24.
11. Hishikawa K, Oemar BS, Nakaki T. 2001. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Che 276: 16797-16803.
12. Ji L, Yin XX,Wu ZM,Wang JY, Lu Q, Gao YY. 2009. Ginkgo biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells. Phytother Res 23: 477-485.
13. Kagami S, Border WA, Miller DE, Noble NA. 1994. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437.
14. Kanwar YS, Wada J, Sun L, et al. 2008. Diabetic nephropathy:mechanisms of renal disease progression. Exp Biol Med 233:4-11.
15. Lai PB, Zhang L, Yang LY. 2012. Quercetin ameliorates diabetic nephropathy by reducing the expressions of transforming growth factor-b1 and connective tissue growth factor in streptozotocin- induced diabetic rats. Ren Fail 34: 83-87.
16. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. 2003. Role of TGFbeta signaling in extracellular matrix production under high glucose conditions. Kidney Int 63: 2010-2019.
17. Lu Q, Yin XX, Wang JY, Gao YY, Pan YM. 2007. Effects of Ginkgo biloba on prevention of development of experimental diabetic nephropathy in rats. Acta Pharmacol Sin 28: 818-828.
18. Mogensen CE, Christensen CK, Vittinghus E. 1983. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32: 64-78.
19. Mulay SR, Gaikwad AB, Tikoo K. 2010. Combination of aspirin with telmisartan suppresses the augmented TGF-beta/ Smad signaling during the development of streptozotocininduced type I diabetic nephropathy. Chem Biol Interact 185: 137-142.
20. Nguyen TQ, Tarnow L, Jorsal A, et al. 2008. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31: 1177-1182.
21. Roy S, Dontamalla SK, Mondru AK, Sannigrahi S, Veerareddy PR. 2011. Downregulation of apoptosis and modulation of TGF-β1 by sodium selenate prevents streptozotocin-induced diabetic rat renal impairment. Biol Trace Elem Res 139: 55-71.
22. Schrijvers BF, Vriese AD, Flyvbjerg A. 2004. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010.
23. Singh R, Alavi N, Singh AK, Leehey DJ. 1999. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48: 2066-2073.
24. Suzuki D, Toyoda M, Yamamoto N, et al. 2006. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 45: 435-441.
25. TangDQ, Zhang ZJ,GaoYY,WeiYQ,Han L. 2009. Protective effects of serumcontaining Ginkgo biloba extract on glomerulosclerosis in rat mesangial cells. J Ethnopharmacol 124: 26-33.
26. Tang DQ, Wei YQ, Yin XX, et al. 2011. In vitro suppression of quercetin on hypertrophy and extracellular matrix accumulation in rat glomerular mesangial cells cultured by high glucose. Fitoterapia 82: 920-926.
27. Tan AL, Forbes JM, Cooper ME. 2007. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143.
28. Wahab NA, Yevdokimova N, Weston BS, et al. 2001. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359: 77-87.
29. Wang JY, Yin XX, Wu YM, et al. 2006. Ginkgo biloba extract suppresses hypertrophy and extracellular matrix accumulation in rat mesangial cells. Acta Pharmacol Sin 27: 1222-1230.
30. Wolf G. 2003. Growth factors and the development of diabetic nephropathy. Curr Diab Rep 3: 485-490.
31. Yuan Y, Zhao L, Chen Y, et al. 2011. Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. Am J Physiol Renal Physiol 301: F236-243.
32. Yu L, Border WA, Anderson I, et al. 2004. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 66: 1774-1784.